Related Experiment Video
Updated: Aug 24, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Growth and sexual maturation during long-term treatment with risperidone
Fiona Dunbar1, Vivek Kusumakar, Denis Daneman
1Janssen-Ortho Inc., Toronto, Ontario, M3C 1L9 Canada.
Objective:
This study assessed the impact of risperidone on growth and sexual maturation.
Method:
The pooled database of five studies included 700 children ages 5-15 years with disruptive behavior disorders. All evaluable patients had received risperidone for 11 or 12 months. Those evaluable for growth also had baseline and 11- or 12-month height measurements (N=350); girls >/=9 years and boys >/=10 years who were evaluable for sexual maturation also had baseline and 11- or 12-month Tanner staging (N=222).
Results:
Risperidone-treated children had a mean increase in height 1.2 cm greater than the reference population, and they experienced no delay in progression through Tanner staging. Transient increases in prolactin did not correlate with growth or sexual maturation.
Conclusions:
In this retrospective analysis, there was no evidence of statistically or clinically significant growth failure or delay in pubertal onset or progression in children treated for up to 1 year with risperidone.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Antipsychotic Drugs: Typical and Atypical Agents
Psychosexual Theory of Development
The Five Stages of Psychosexual Development
Freud's psychosexual...
Pharmacodynamics in Geriatric Patients: Effects of Age
